Introduction
Multiple myeloma (MM) accounts for B1% of all malignant diseases and more than 10% of hematological malignancies in United States.
1 Despite the development of new, highly effective chemotherapies, MM is still an incurable disease. Autologous stem cell transplant has been shown to prolong survival and decrease relapse rates compared to conventional chemotherapies in selected patient populations.
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Double autologous transplant (tandem) has been shown to increase survival among patients with MM, especially those who do not have a very good partial response after undergoing a single transplant. [5] [6] [7] Therefore, when initially selecting chemotherapy, the effects on the ability to collect a sufficient number of stem cells for more than one transplant must be taken into consideration. Until recently, the standard first line therapy for MM was combination therapy with alkylating agents and dexamethasone; [8] [9] [10] [11] [12] however, the limited response rates and unsatisfactory side effects of these therapies led to the development of new drugs. Thalidomide (Thalomid; Celgene, Summit, NJ, USA) was the first immunomodulatory agent to be studied in MM. In combination with dexamethasone, thalidomide was found to improve OS rate and decrease the relapse rate. [13] [14] [15] [16] [17] More recently, lenalidomide (Revlimid; Celgene) has been shown to have increased efficacy than thalidomide and fewer undesirable side effects. Randomized trials have demonstrated favorable results when lenalidomide is combined with dexamethasone in patients with relapsed or refractory MM. [18] [19] [20] [21] As lenalidomide is known to cause BM suppression, concerns have been raised regarding its impact on the number of stem cells that can be collected in patients who received lenalidomide as part of their induction therapies (Kumar et al., 22 Mazumdar et al.
23
). In this study, we retrospectively analyzed the results of stem cell mobilization and collection in patients with MM who received lenalidomide and dexamethasone (len/dex) as part of induction chemotherapy and then mobilized with either G-CSF/CY or G-CSF alone to those patients who received other induction therapies.
Materials and methods

Patients
This study is a retrospective analysis of 364 patients who were diagnosed with MM and underwent stem cell mobilization and harvest or attempted harvest at the University of Pennsylvania Abramson Cancer Center between January 2002 and December 2007. The medical charts were reviewed retrospectively.
Protocol inclusion/exclusion
All patients who were diagnosed with MM, underwent stem cell mobilization at the University of Pennsylvania Abramson Cancer Center and had their treatment regimens documented in the medical record were included in the study. Of the 364 patients who met the initial inclusion criteria, 74 patients were excluded from the data analysis including 23 with incomplete data on induction regimen, 19 with incomplete data on stem cell collection, 16 with incomplete data on mobilization regimen, 10 who underwent allogeneic transplants, 2 who had autologous BM harvests, 2 who had PSCs collected at an outside institution, and 2 who had medical complications before harvest and after mobilization (1 patient with gastrointestinal bleeding, 1 patient with intracranial hemorrhage). There were 290 patients in the final analysis.
Treatment regimens
All patients were treated with either a single regimen or multiple regimens to obtain a response before stem cell mobilization. VAD (vincristine, adriamycin, dexamethasone), DVD (pegylated doxorubicin, vincristine, dexamethasone), dexamethasone alone, thalidomide/dexamethasone, len/dex, and bortezomib/dexamethasone accounted for 89% of the regimens that were used. The median number of regimens used to obtain remission was one (range 1-4).
Failure to collect
Failure to collect was defined as failure to collect more than 2.0 Â 10 6 CD34 þ cells/kg or failure to initiate collection because of inadequate circulating CD34 þ stem cells (o6 cell/mL).
Mobilization regimen
Stem cell mobilization was either with G-CSF or G-CSF and CY, at the attending physician's discretion. G-CSF was used at a dose of 10 mg/kg subcutaneously starting 5 days before the first planned stem cell collection and continued until the goal of 6 Â 10 6 CD34/kg was obtained, a maximum of 10 collections, or the decision was made to discontinue based on decreasing numbers of collected cells. When G-CSF /CY was used the CY was dosed at 3.0 g/m 2 for one dose and G-CSF 10 mg/kg subcutaneously starting 5 days after CY and continued as above.
Statistical analysis
The 290 patients were divided into two groups. The first group consisted of 43 patients whose treatment regimen included len/dex. The second group consisted of 247 patients in whom len/dex was never used. The first group was divided into two subgroups: 18 patients that received len/dex alone and 25 patients who received len/dex as one of multiple sequential regimens. The second group was divided into two subgroups as well: 184 patients who received one regimen only and 63 patients who received multiple sequential regimens (Figure 1 ). The Wilcoxon rank sum test was used to compare the groups.
Results
Single induction regimen regardless of the mobilization regimen Among the 290 patients who were evaluated, 202 were treated with only one type of chemotherapy; 18 received len/dex alone and 184 received a single non-lenalidomide containing regimen. The median number of CD34 þ collected was 6.5 Â 10 6 /kg and 7.05 Â 10 6 /kg, respectively (P ¼ 0.06). The median number of apheresis cycles was two in both groups. One patient from the len/dex group failed to achieve a sufficient number of stem cells for collection, whereas three patients (2%) from the non-len/dex group failed in this respect. The number of collected stem cells was lower when len/dex was used; however, the difference was not clinically significant (Table 1) .
Multiple induction regimens regardless of the mobilization regimen In those patients who were treated with sequential therapies, 25 patients received len/dex as one of their regimens whereas 63 patients received multiple therapies not including len/dex. The median number of collected stem cells was 5.4 Â 10 6 /kg and 6.3 Â 10 6 /kg, respectively (P ¼ 0.91) and the failure rate was 12% (3/25) and 11% (7/63), respectively (P ¼ NS). There was also no difference in the mean number of collected stem cells (Table 1) .
G-CSF vs G-CSF/CY
Of the 290 patients, the most common mobilization regimens were G-CSF/CY (197 patients) and G-CSF alone (58 patients). The median number of apheresis was two and four cycles, respectively (Po0.01), whereas the median number of collected stem cells was 7.7 Â 10 6 /kg and 4 Â 10 6 / kg, respectively (Po0.01). Notably, 72% (142/197) of the patients who received G-CSF/CY were able to collect X6 Â 10 6 /kg CD34 þ compared with 19% (11/58) of patients who received G-CSF alone (Table 2) . The failure rate in the lenalidomide-treated group was higher when G-CSF was used alone 33% (2/6) in comparison with G-CSF/CY 6% (2/24), though the number of patients who received G-CSF alone was small (Table 3 ).
The percentage of the patients collecting X6 Â 10 6 CD34 þ cells/kg The percentage of the patients who collected X6 Â 10 6 CD34 þ cells/kg and received len/dex as a single induction regimen or as part of multiple induction regimens was 58% (25/43), and it was 62% (155/247) in the patients who did not receive len/dex before transplant (P ¼ 0.25) ( Table 4) .
Lenalidomide cycles and the number of collected stem cells Among those patients who were treated with lenalidomide, the number of lenalidomide cycles ranged from 1 to 16 (median of four cycles). Fifty-six percent (24/43) of lenalidomide-treated patients received four cycles or fewer of lenalidomide and 44% (19/43) received more than four cycles. The median number of collected stem cells in patients who received more than four cycles of len/dex was the same, 6.4 Â 10 6 CD34 þ cells/kg in the patients who received less than or equal to four cycles of len/dex (P ¼ 0.43).
Discussion
High-dose chemotherapy with autologous stem cell transplant is a treatment that has been shown to prolong disease-free survival rate and OS in patients with symptomatic MM younger than 70-years old.
2-4 Studies are on-going, but have not determined the ideal timing for transplant. Studies have not yet shown significant differences between early transplant, (first-line therapy), or late, (rescue treatment), except for a shorter period of chemotherapy with the former. 24 Tandem transplant has been shown to increase the OS among patients with refractory MM, especially those who do not attain a good partial response after one transplant. [5] [6] [7] Consequently, higher numbers of stem cells should be collected to enable multiple transplants, and consideration should be taken regarding the impact of the induction therapy on the ability to collect sufficient number of stem cells.
Thalidomide was the first immunomodulatory agent to be used in MM. In the first line setting, the combination of thalidomide and dexamethasone is associated with high response rates. [13] [14] [15] [16] [17] Studies have shown no impact of thalidomide on stem cell collection, and over 80% of the patients who received thalidomide and dexamethasone were able to collect enough cells for tandem transplant. 25 Lenalidomide, an analog of thalidomide, was developed in an effort to improve the efficacy and decrease the side effects of thalidomide. In combination with dexamethasone, lenalidomide improves the response and the survival rate in patients with MM. [18] [19] [20] [21] Owing to its myelosuppresion, Figure 1 Schema describing patient selection for the study. FTC ¼ failure to collect; len/dex ¼ lenalidomide and dexamethasone. performed a cohort study of 562 patients with MM examining stem cell yields using different induction chemotherapy regimens. They observed a decrease in total CD34 þ cells collected, decreased average daily collections, decreased day 1 collection, and increased numbers of aphereses in patients treated with lenalidomide compared with those receiving other regimens. A trend was seen toward decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age. The authors recommended collection of PBSC within 6 month of lenalidomide therapy to minimize the risk of mobilization failure. Similar results were found in a study by Mazumdar et al., however, the length of lenalidomide therapy did not correlate with the number of stem cells collected. 23 This is in contrast to the results from a prospective study in which sufficient numbers of stem cells for two autologous transplants were collected from all patients who were mobilized with CY and G-CSF after initial treatment with clarithromycin, lenalidomide, and dexamethasone (BiRD). They also did not find the number of lenalidomide cycles to be a limiting factor for successful stem cell mobilization. 26 The data reported here from our single institution analysis suggest that combined CY and G-CSF is an adequate mobilization regimen when lenalidomide is used as part of the initial therapy for myeloma. Our study showed that lenalidomide induction therapy does not prevent collection of adequate numbers of stem cells for more than one transplant when G-CSF and CY are used together for mobilization. The mean stem cell yields are lower for patients who have taken lenalidomide compared with those patients on non-lenalidomide containing regimens; however, the difference is not clinically significant. Increased failure rate is seen in patients when they mobilized with G-CSF compared with G-CSF/CY regardless of induction regimen. Most importantly, the number of lenalidomide cycles does not correlate with stem cell yield.
In conclusion, the incorporation of lenalidomide into induction therapy for MM did not have a clinically significant impact on stem cell collection before autologous stem cell transplantation when CY and G-CSF were used as the mobilization regimen at our institution. G-CSF alone was an inferior mobilization regimen in our study whether or not lenalidomide was used as part of the initial therapy and these data suggest alternative approaches should be considered. The new CXCR4 antagonist, plerixifor (Mozobil), when combined with G-CSF has been shown to be superior to G-CSF alone for stem cell collection before stem cell transplantation for myeloma. 27 Further investigation of this combination in the setting of lenalidomide induction is warranted.
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